Perspective Therapeutics (CATX) Accumulated Expenses (2011 - 2026)

Perspective Therapeutics has disclosed Accumulated Expenses across 16 years of filings, most recently posting $3.9 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $3.9 million, up 33.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.9 million (up 33.1% YoY), and the FY2025 annual result was $7.5 million, up 36.71% from the prior year.
• Accumulated Expenses came in at $3.9 million for Q1 2026 at Perspective Therapeutics, down from $7.5 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $7.5 million in Q4 2025 to a low of $253000.0 in Q2 2022.
• The 5-year median for Accumulated Expenses is $2.6 million (2024), against an average of $2.8 million.
• Across the five-year window, Accumulated Expenses declined 2.32% in 2022 and jumped 1158.95% in 2023, its largest moves.
• Perspective Therapeutics' Accumulated Expenses stood at $285000.0 in 2022, then surged by 1158.95% to $3.6 million in 2023, then soared by 52.68% to $5.5 million in 2024, then jumped by 36.71% to $7.5 million in 2025, then sank by 48.24% to $3.9 million in 2026.
• The last three Accumulated Expenses figures came in at $3.9 million (Q1 2026), $7.5 million (Q4 2025), and $6.7 million (Q3 2025), per Business Quant data.